{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:06:55Z","timestamp":1753877215128,"version":"3.41.2"},"reference-count":41,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["25-A-1","28-A-1"],"award-info":[{"award-number":["25-A-1","28-A-1"]}]},{"name":"Ministry of Health, Labour and Welfare of Japan"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ck0106354"],"award-info":[{"award-number":["JP18ck0106354"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Our phase II trial (FABRIC study) failed to verify the efficacy of gemcitabine plus oxaliplatin (GEMOX) in patients with pancreatic ductal adenocarcinoma (PDAC) with a familial or personal history of pancreatic, breast, ovarian or prostate cancer, which suggested that a family and personal history may be insufficient to determine response to platinum-based chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This ancillary analysis aimed to investigate the prevalence of germline variants of homologous recombination repair (HRR)-related genes and clarify the association of germline variants with the efficacy of GEMOX and patient outcome in PDAC patients. Of 45 patients enrolled in FABRIC study, 27 patients were registered in this ancillary analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the identified variants in HRR-related genes, one variant was considered pathogenic and eight variants in six patients (22%) were variants of unknown significance (VUS). Objective response to GEMOX was achieved by 43% of the seven patients and tended to be higher than that of patients without such variants (25%). Pathogenic\/VUS variant in HRR-related genes was an independent favorable factor for progression-free survival (hazard ratio, 0.322; P\u00a0=\u00a00.047) and overall survival (hazard ratio, 0.195; P\u00a0=\u00a00.023) in multivariable analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The prevalence of germline variants in PDAC patients was very low even among patients with a familial\/personal history of pancreatic, breast, ovarian or prostate cancer. Patients with one or more germline variants in HRR-related genes classified as pathogenic or VUS may have the potential to obtain better response to GEMOX and have better outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyac110","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T13:04:03Z","timestamp":1663851843000},"source":"Crossref","is-referenced-by-count":1,"title":["Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-0101","authenticated-orcid":false,"given":"Takeshi","family":"Terashima","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Kanazawa University Hospital , Kanazawa , Japan"},{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineko","family":"Ushiama","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine and Services, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shiba","sequence":"additional","affiliation":[{"name":"Division of Cancer Genomics, National Cancer Center Research Institute , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , Kashiwa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , Kashiwa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Cancer Center Hospital , Nagoya , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ishikawa Prefectural Central Hospital , Kanazawa , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohichiroh","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine , Kyoto , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Azemoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shikoku Cancer Center , Matsuyama , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kobe City Medical Center General Hospital , Kobe , Japan"},{"name":"Department of Medical Oncology, Kochi Medical School , Kochi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Nomura","sequence":"additional","affiliation":[{"name":"Biostatistics Division, Center for Research Administration and Support, National Cancer Center , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Yachida","sequence":"additional","affiliation":[{"name":"Department of Cancer Genome Informatics , Graduate School of Medicine, , Osaka , Japan"},{"name":"Osaka University , Graduate School of Medicine, , Osaka , Japan"},{"name":"Division of Genomic Medicine, National Cancer Center Research Institute , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kokichi","family":"Sugano","sequence":"additional","affiliation":[{"name":"Department of Genetic Medicine and Services, National Cancer Center Hospital , Tokyo , Japan"},{"name":"Department of Genetic Medicine, Kyoundo Hospital, Sasaki Foundation , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kyorin University Faculty of Medicine , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"2022092212482310300_ref1","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"2022092212482310300_ref2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2022092212482310300_ref3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2468-1253(19)30416-9","article-title":"Early detection of pancreatic cancer","volume":"5","author":"Pereira","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022092212482310300_ref4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3748\/wjg.v23.i6.935","article-title":"Familial pancreatic cancer: concept, management and issues","volume":"23","author":"Matsubayashi","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2022092212482310300_ref5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yasu.2010.05.011","article-title":"Update on familial pancreatic cancer","volume":"44","author":"Hruban","year":"2010","journal-title":"Adv Surg"},{"key":"2022092212482310300_ref6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10637-017-0497-1","article-title":"Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing","volume":"36","author":"Lee","year":"2018","journal-title":"Invest New Drugs"},{"key":"2022092212482310300_ref7","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022092212482310300_ref8","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.esmoop.2020.100032","article-title":"Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort","volume":"6","author":"Peretti","year":"2021","journal-title":"ESMO Open"},{"key":"2022092212482310300_ref9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma","volume":"76","author":"Fogelman","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022092212482310300_ref10","first-page":"1835","article-title":"Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic\/breast\/ovarian\/prostate cancer or personal history of breast\/ovarian\/prostate cancer (FABTIC study)","volume":"25","author":"Okano","year":"2020","journal-title":"Int J Cancer"},{"key":"2022092212482310300_ref11","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022092212482310300_ref12","doi-asserted-by":"crossref","first-page":"19817","DOI":"10.18632\/oncotarget.24865","article-title":"Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer","volume":"9","author":"Kondo","year":"2018","journal-title":"Oncotarget"},{"key":"2022092212482310300_ref13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and soatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022092212482310300_ref14","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","article-title":"Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer","volume":"23","author":"Zhao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022092212482310300_ref15","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/cncr.30808","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"Pomerantz","year":"2017","journal-title":"Cancer"},{"key":"2022092212482310300_ref16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with burrows\u2013wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2022092212482310300_ref17","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"2022092212482310300_ref18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A map of human genome variation from population-scale sequencing","volume":"467","author":"1000 Genomes Project Consortium","year":"2010","journal-title":"Nature"},{"key":"2022092212482310300_ref19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11632","volume":"491","author":"1000 Genomes Project Consortium","year":"2012","journal-title":"Nature"},{"key":"2022092212482310300_ref20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"2022092212482310300_ref21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/ng.2854","article-title":"Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database","volume":"46","author":"Thompson","year":"2014","journal-title":"Nat Genet"},{"key":"2022092212482310300_ref22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/humu.21629","article-title":"Classification of missense substitutions in the BRCA genes: a database dedicated to ex-UVs","volume":"33","author":"Vallee","year":"2012","journal-title":"Hum Mutat"},{"key":"2022092212482310300_ref23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nprot.2009.86","article-title":"Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm","volume":"4","author":"Kumar","year":"2009","journal-title":"Nat Protoc"},{"key":"2022092212482310300_ref24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nat Methods"},{"key":"2022092212482310300_ref25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"Mutation Taster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat Methods"},{"key":"2022092212482310300_ref26","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/bioinformatics\/btt182","article-title":"Predicting the functional consequences of cancer-associated amino acid substitutions","volume":"29","author":"Shihab","year":"2013","journal-title":"Bioinformatics"},{"key":"2022092212482310300_ref27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10689-017-9985-x","article-title":"Molecular characterization and clinical interpretation of BRCA1\/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers","volume":"16","author":"Barrios","year":"2017","journal-title":"Fam Cancer"},{"journal-title":"J Natl Compr Canc Netw.","key":"2022092212482310300_ref28"},{"key":"2022092212482310300_ref29","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/j.1349-7006.2008.00944.x","article-title":"Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast\/ovarian cancer","volume":"99","author":"Sugano","year":"2008","journal-title":"Cancer Sci"},{"key":"2022092212482310300_ref30","doi-asserted-by":"crossref","first-page":"74227","DOI":"10.18632\/oncotarget.12490","article-title":"Germline mutations in Japanese familial pancreatic cancer patients","volume":"7","author":"Takai","year":"2016","journal-title":"Oncotarget"},{"key":"2022092212482310300_ref31","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.18632\/oncotarget.27224","article-title":"Germline mutations in cancer-predisposition genes in patients with biliary tract cancer","volume":"10","author":"Terashima","year":"2019","journal-title":"Oncotarget"},{"key":"2022092212482310300_ref32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022092212482310300_ref33","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s12282-020-01119-7","article-title":"Retrospective reinterpretation and classification of BRCA1\/2 variants from Chinese population","volume":"27","author":"Li","year":"2020","journal-title":"Breast Cancer"},{"key":"2022092212482310300_ref34","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1038\/s41598-021-87792-w","article-title":"Analysis of BRCA1\/2 variants of unknown significance in the prospective hereditary breast cancer study","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"2022092212482310300_ref35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fmolb.2020.00169","article-title":"Functional characterization of PALB2 variants of uncertain significance: toward cancer risk and therapy response prediction","volume":"7","author":"Boonen","year":"2020","journal-title":"Front Mol Biosci"},{"key":"2022092212482310300_ref36","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1007\/s13277-016-5109-8","article-title":"Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the tumor Bank ovarian cancer (TOC)","volume":"37","author":"Dimitrova","year":"2016","journal-title":"Consortium Tumour Biol"},{"key":"2022092212482310300_ref37","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1245\/s10434-020-08469-8","article-title":"Increasd rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer","volume":"27","author":"Golan","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2022092212482310300_ref38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br J Cancer"},{"key":"2022092212482310300_ref39","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jjco\/hyy132","article-title":"Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis","volume":"48","author":"Terashima","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"2022092212482310300_ref40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2022092212482310300_ref41","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","article-title":"A phase I\/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer","volume":"26","author":"Pishvaian","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyac110\/45050003\/hyac110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyac110\/45050003\/hyac110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T13:04:51Z","timestamp":1663851891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyac110\/6648800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac110","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"article-number":"hyac110"}}